Neurocrine Biosciences' Management Presents At Morgan Stanley Global Healthcare Conference - Transcript

Neurocrine Biosciences, Inc. (NBIX)

Morgan Stanley Global Healthcare Conference Call

September 12, 2012 08:00 AM ET

Executives

Kevin C. Gorman - President, CEO

Analysts

Presentation

Question-and-Answer Session

Unidentified Analyst

It is my pleasure to introduce Kevin Gorman, President and CEO of Neurocrine Biosciences. And I think just to start, if you can give us a brief overview of what you guys have going on currently?

Kevin C. Gorman

Sure, [Sarah]. Thank you very much and thank you to Morgan Stanley for the opportunity to come today and speak. I will be making forward-looking statements throughout this Q&A. So, I would like you to – direct you to our recent SEC filings for all the risk factors associated with that. Neurocrine Biosciences is a neuroendocrine Company. We have two main programs that are going on in the Company today and I think that most of our questions are going to center around that and I do look forward to taking any questions that you all might have. The first program is our GnRH program. The lead compound is called Elagolix. It’s partnered with Abbott Pharmaceuticals. Abbott has the drug in the Phase 3 trial for endometriosis and they have it in a Phase 2 proof-of-concept trial ongoing in uterine fibroids.

This is a program that was discovered at Neurocrine approximately 11 years ago and we formed a relationship with Abbott approximately 2.5 years ago. The second program which was wholly owned by Neurocrine and again completely all the discovery was done at Neurocrine starting about five years ago is a VMAT2 inhibitor. VMAT2 is a presynaptic target, Vesicular Mono-Amine Transporter and we have this – currently we’re going to be starting Phase 2b study in Tardive Dyskinesia and Tardive Dyskinesia is a movement disorder that is caused by antipsychotic drugs.

If you liked this article you might like

10 Sectors That Will Profit Big-Time From Oil's Crash

Biotech Movers: Inovio, Neurocrine, Alnylam

Week in Review: Wall Street Sees Red as Geopolitical Issues Dominate, Earnings Begin

U.S. Markets Close Lower as Wall Street Frets Over Global Turmoil

Wall Street Closes Lower Amid Continued Global Worries